Core Insights - The "Nansha Plan" has successfully achieved its first phase goals by 2025, positioning Nansha as a significant national strategic platform that integrates the Greater Bay Area, collaborates with Hong Kong and Macau, and engages with the global market [1] Tax Incentives and Economic Growth - Since the implementation of three regional tax incentives under the "Nansha Plan" in 2022, a total of 2.1 billion yuan has been saved in tax reductions for enterprises, and 150 million yuan in personal income tax has been waived for Hong Kong and Macau residents, resulting in an average tax burden reduction of over 50% [1] - Guangzhou Jiesen Entertainment Development Co., Ltd. reported a sixfold increase in sales revenue in 2024, attributed to the supportive policies of the "Nansha Plan" [2] - The Qingsheng Hub area, a pilot zone in Nansha, has seen a fivefold increase in the number of Hong Kong and Macau enterprises over three years, with over 210 registered and settled companies [2] Healthcare and Innovation - The "Nansha Opinions" have initiated institutional reforms in the fields of biomedicine and intelligent unmanned systems, allowing for clinical applications of restricted cell transplantation technologies [3] - Nansha has achieved significant breakthroughs in cell and gene therapy, including the first clinical application of Mediterranean anemia treatment and the first allogeneic stem cell treatment for liver failure [3] - By June 2025, 38 patients with Mediterranean anemia had successfully been discharged after treatment in Nansha, demonstrating accelerated clinical application [3] Financial Support and Cross-Border Financing - The "Nansha Financial 30 Measures" aim to enhance cross-border financing efficiency, addressing traditional challenges such as lengthy approval processes and strict capital controls [3] - The first foreign currency direct loan for a financial leasing company in Guangdong Province was successfully executed, along with an expanded foreign debt quota for a subsidiary of China Southern Airlines International Financing Leasing [3] Climate Financing and Sustainable Development - Nansha has been recognized for three consecutive years as the best in institutional innovation within Guangdong Free Trade Zone and has developed the first set of local standards for climate financing cooperation among Guangzhou, Hong Kong, and Macau [4] - Innovative financial products such as the first "climate financing guarantee" loan and the first "climate financing + rural revitalization" sustainable development-linked loan have been introduced [4] - Nansha aims to create a high-quality development loop through the integration of industrial incentives, institutional innovation, and financial support, establishing itself as an ideal location for investment and innovation [4]

本届大会上，海医汇集中发布了10余项技术，覆盖血液与健康生态、细胞与基因治疗、高端科研仪器、 罕见病诊疗、脑重大疾病防治及AI+重大疾病防治等多个前沿领域。同时，海医汇携手生态伙伴于本届 大会上发起"汇聚AI智慧，促进医疗共融共创新范式"倡议，旨在以AI技术驱动科研范式变革，共同推动 AI技术在医疗健康领域的深度融合与转化应用，加速科技创新成果从实验室走向临床普惠。 此外，海尔盈康一生与首都医科大学再度携手，于本届大会上启动"科创菁英培育计划"二期，将进一步 拓展合作广度与培育深度，共同搭建贯通"基础-临床-转化"的协同培育体系，助力更多青年科研人才 将"想法"转化为"成果"。 12月19日，以"Al for Health·助力健康中国2030"为主题的第二届海医汇医疗科技创新生态大会在北京召 开。本届大会由中国研究型医院学会、中国医学科学院北京协和医学院、广州实验室主办，海医汇承 办，北京脑重大疾病研究院为支持单位，《医师报》社为战略支持媒体。大会汇聚知名院士、专家学者 及行业领军企业代表，共同探讨在AI与科技驱动下，跨越从基础研究到产业应用的"达尔文之海"，构建 科研与产业协同新范式，为医疗健康领域新质生 ...

Core Insights - The joint policy from three ministries in January 2024 has significantly accelerated the development of the cell and gene therapy industry in Nansha, allowing clinical applications of restricted cell transplantation technologies under certain conditions [1][3] - The establishment of three major public service centers in Nansha aims to enhance the infrastructure for cell and gene therapy, focusing on clinical application, safety evaluation, and data management [1][4] Group 1: Infrastructure Development - The Guangdong Jihe Stem Cell Engineering Co., Ltd. is leading the construction of a clinical-grade seed cell bank in Nansha with a total planned investment of 200 million yuan, which will facilitate the research and clinical transformation of cell technology [3][4] - The public service center in Nansha will serve as a national-level platform integrating high-precision quality testing, intelligent sample storage, and comprehensive data management for cell therapy [9][10] Group 2: Evaluation and Safety - The establishment of the Bay Area Biological Therapy Health Effect Evaluation Center aims to create an internationally leading evaluation system for the safety, effectiveness, and health effects of biological therapies, addressing key challenges in clinical translation [5][6] - The center will focus on four core areas: multi-dimensional efficacy evaluation of cell therapies, research on side effects, precise immune assessment, and biological age prediction for health intervention [6][7] Group 3: Industry Collaboration and Growth - Nansha is positioned to leverage its geographical advantages and resources from the Greater Bay Area to build a global innovation hub for biological therapy, attracting industry experts and fostering collaboration among over 400 biopharmaceutical companies [12][13] - The integration of data accumulation and AI technology is expected to enhance treatment efficacy and optimize patient care in the field of biological therapy [13]